Abstract: This study was aimed to develop nanostructured lipid carriers (NLC) for the possible delivery of mefenamic acid. This study describes the effect of liquid lipid concentration on the characteristics of NLC such as particle size, polydispersity index, zeta potential, drug entrapment efficiency, and occlusivity index. Transmission electron microscopy revealed nearly spherical shape NLC with negligible effect of liquid lipid content on the particle morphology. The differential scanning calorimetry demonstrated a depression in the melting point and crystallinity index of the NLC with an increase in the amount of liquid lipid. The in vitro drug release studies demonstrated that solid lipid nanoparticle (0% oil), and NLC possessed a biphasic release pattern characterised by a rapid initial release followed by a sustained release, in comparison to nanoemulsions (100% oil) of which a nearly constant release was observed. Compared to NE and SLN, the excellent physical stability of NLC against drug leakage was seen.
Introduction
In recent years, significant efforts have been devoted to the use of colloidal drug delivery systems including nanoparticles, nanocapsules, micelles, nanoliposomes etc. since they display a great potential for the transport of bioactive with the focus on enhancing drug bioavailability, controlled and site-specific delivery, and reduced toxicity. The development of solid lipid nanoparticles (SLNs) has received considerable attention because of the good tolerability due to the use of physiological and biodegradable lipids, site-specific targeting, controlled drug release, wide potential application spectrum (dermal, peroral, intravenous) , successful incorporation of lipophilic as well as hydrophilic drugs and protection of sensitive drug molecules from degradation (Uner and Yener, 2007; Utreja and Jain, 2001; Wang et al., 2002; Chen et al., 2006) . However, SLN are known for unpredictable gelation tendency, burst drug release, limited drug loading capacity due to crystalline structure of solid lipid and drug expulsion during storage due to polymorphic transformation of the lipid crystals (Muller et al., 1995; Mehnert and Mader, 2001; Muller et al., 2002a Muller et al., , 2002b . Nanostructured lipid carriers (NLCs) have been developed to overcome the limitations of SLN. NLC have been explored for dermal delivery in cosmetics and dermatological preparations. The main advantages of NLC arise from the composition of their lipid matrix, which is made from blend of solid and liquid lipids. . Most of the used lipids have an approved status for human use due to their low toxicity or are the excipients used in topical cosmetic or pharmaceutical preparations. Owing to their small size, they act as occlusives, i.e., they form a film on the skin and thereby enhance the penetration of drugs through stratum corneum. Further, they have skin deposition potential and work well for sustained release owing to the possible formation of a drug reservoir (Khurana et al. 2009; Lacerda et al., 2011; Gonzalez-Mira et al., 2011) .
Mefenamic acid (MFA) is a non-steroidal anti-inflammatory agent possessing analgesic and antipyretic activities. Oral therapy with MFA is effective, but clinical use is often limited because of serious adverse systemic effects and gastrointestinal irritation at the usual dose of oral administration after prolonged use. Further, the very poor aqueous solubility of MFA give rise to difficulties in the design of pharmaceutical formulations and low oral bioavailability from solid dosage forms. Although the transdermal drug delivery system is a convenient system to bypass disadvantages of the oral route like local gastrointestinal adverse events and adverse systemic effects, but the formidable skin barrier prevents the percutaneous absorption of drugs.
The main objective of this study was to develop NLCs for the possible delivery of MFA. Being highly lipophilic, MFA is an excellent candidate for NLC encapsulation. Factors influencing the NLC formation were determined and optimised. To investigate the effect of liquid lipid concentration on the characteristics of the NLC such as particle size, particle morphology, polydispersity index (PI), zeta potential, crystallinity index (CI), drug entrapment efficiency (E.E), drug release rate, occlusion factor etc., formulations with increasing concentration of the liquid lipid (0-100% w/w based on solid lipid; 0% w/w being SLN, and 100% w/w being nanoemulsion, NE) were prepared and characterised.
Materials and methods

Materials
MFA was obtained as a gift from Lupin Pharmaceuticals Ltd., Goa, India, cetyl palmitate (CP), isopropyl myristate (IPM), caprylic acid (CA), oleic acid (OA), propylene glycol (PG), Tween 80 (T80), polyethylene glycol 400 (PEG 400) were purchased from S D Fine Chemicals, Mumbai, India. All other chemicals were of the analytical grade and used as received.
Selection of components for NLC formulation
In order to select the components for NLC formulation, drug solubility in the surfactant(s), co-surfactant(s) and liquid lipid was determined. Briefly, an excess of pure drug was added separately to 5 mL each of liquid lipid, surfactant and co-surfactant in screw capped tubes and equilibrated for 72 hr at 37 ± 1°C (Khurana et al., 2010) . The saturated solutions were centrifuged at 3,000 rpm for 10 min and the supernatants were suitably diluted with methanol and analysed in a UV spectrophotometer (Hitachi U-2800 spectrophotometer, Tokyo, Japan) at 285 nm.
Preparation of free and drug loaded NLCs from microemulsion precursors
The NLC were prepared using a modified literature method named microemulsion template strategy (Cui and Mumper, 2002; Oyewumi and Mumper, 2002; Khurana et al., 2010) . Firstly, a calculated volume of T80 and PG stock solutions was added to the hot homogeneous milky slurry composed of water and lipid phase (blend of solid lipid and liquid lipid) at 65°C, with continuous stirring on magnetic stirrer to obtain a clear microemulsion. Subsequently, the NLC dispersions were formed simply by cooling the warm microemulsion precursor to room temperature in the same container. To study the effect of liquid lipid concentration on the characteristics of the NLC, dispersions with increasing concentration of the liquid lipid (10%, 15%, 25%, 35%, 40%, 100% w/w based on solid lipid) were prepared. The total amount of lipid phase was kept constant (10% w/v) in all formulations. The drug loaded NLCs were prepared after replacing a definite amount of the lipid phase by MFA.
Characterisation of the NLC
Particle size and zeta potential analysis
The mean particle size (z-ave), the PI and zeta potential of various formulations was determined by photon correlation spectroscopy (PCS) in a Malvern Nanosizer ZS (Malvern Instruments, UK) at 25°C in disposable sizing cuvettes. Prior to the measurement, the PCS sample was diluted 10-fold with double distilled water to a suitable scattering intensity. The conductivity of this solution was adjusted to 50 mS/cm by 0.1 mmoL/L sodium chloride solution for measurement of zeta potential.
Surface morphology
The surface morphology of all formulations was studied by transmission electron microscopy (TEM, Philips, Amsterdam, Netherlands) using phosphotungstic acid (PTA) as negative stain.
Drug E.E
Drug E.E was calculated by determining the amount of drug entrapped (A 2 ) after removal of unentrapped drug using dialysis bag (Sigma, USA; MWCO 12000-14000) (Washington, 1989) . The dialysed formulation was lysed using Triton-X 100 (0.1% v/v) and subsequently analysed for drug content (A 2 ). Drug E.E was calculated by using the equation (1):
where A 1 is the total amount of drug added in the formulation. The concentration of drug was determined by UV spectrophotometry (Hitachi U-2800 spectrophotometer, Tokyo, Japan) at 285 nm.
Differential scanning calorimetry
Thermal behaviour of the different dispersions was studied in a differential scanning calorimeter (DSC, Mettler Toledo, 821e, Switzerland) . Weighed amounts of the samples (approximately 1-3 mg based on lipid content) were placed in 40 μL aluminium pans. An empty aluminum pan was used as a reference. The scans were performed between 25-85°C at heating rate of 5 K/min. The DSC parameters were evaluated using STAR e Software (Mettler Toledo, 821e, Switzerland). Melting points correspond to the maximum of the heating curve. CI was calculated using equation (2) (Washington, 1989 
In vitro release
In vitro release profile of MFA from formulations was determined using the dialysis bag technique (Sigma, USA; MWCO 12000-14000) (Yang et al., 1999) . Because of the low solubility of MFA in water and acetate buffer (pH 6.0), acetate buffer (pH 6.0) with 1% w/v cetyltrimethylammonium bromide (CTAB) was selected as acceptor medium. Free drug from the formulation was removed by dialysis for 24 hr. against acceptor medium at 4°C. One ml of dialysate was introduced into prewashed dialysis bag, which was placed in a beaker containing 50 mL of acceptor medium. The experiments were performed at 32°C for 9 hr. under constant magnetic stirring at 50 rpm. Sample aliquots (2 mL) were withdrawn periodically and replaced immediately with a similar volume of fresh medium, centrifuged, and analysed by UV spectrophotometry (Hitachi U-2800 spectrophotometer, Tokyo, Japan) at 285 nm to determine the drug release rate from the formulation.
Occlusion test
In vitro occlusivity test was conducted following the method reported by De Vringer and De Ronde (1995) . Briefly, 100 ml beakers with a diameter of 4.9 cm were filled with 50 mL of water, covered with filter paper (cellulose acetate filter) and sealed. Two hundred milligram of formulation was spread evenly on the filter surface (18.8 cm 2 ). These beakers were then stored at 32 ± 1°C (skin temperature) for a period of 48 hr. Another beaker covered with filter paper without formulation was taken as control. The beakers were weighed after 6, 24 and 48 hr. The water loss or water flux through the filter paper at each time point was calculated. The occlusion factor (F) was calculated using the following equation:
where A is the water flux through the filter paper without sample (control) and B is the water flux through the filter paper with sample.
Evaluation of storage stability
All the formulations were subjected to long-term stability tests. All the dispersions were stored in screw capped glass vials at 4 ± 1°C, 25 ± 1°C, 40 ± 1°C over time (21 days), and the stability was periodically monitored for the organoleptic changes, physicochemical properties like particle size, PI, zeta potential and drug content at regular time intervals. The turbidity was measured photometrically (Hitachi U-2800 Spectrophotometer, Tokyo, Japan) at 450nm at regular time intervals to assess particle aggregation. Binocular microscope (Labomed vision -2000, India) at 100X, 400X, and 1000X magnification was used to monitor the appearance of drug crystals in all formulations at predetermined time intervals.
Statistical analysis
All the results were expressed as mean ± standard deviation (S.D.). Data was analysed using Student's t-test or one-way ANOVA followed by Tukey or Dunnett's t-test (Sigma Stat Software, 3.5, Systat software, Inc USA). p-values <0.05 were considered as statistically significant.
Results
Selection of lipid matrix and preparation of NLC
To study the lipid solubility of MFA, a range of liquid lipids like OA, IPM, and CA was selected. Figure 1 shows 
Physicochemical characterisation of SLN, NLC and NE
Macroscopically, SLN and all the NLC formulations were milky, homogeneous systems while NE was transparent. pH value of all the formulations ranged between 5.8-6.0. Table 1 shows the effect of CA concentration on mean diameters, PIs and zeta potential of the NLC. A trend towards the decrease in particle size with the increase in CA content was observed. The PI of all formulations ranged between 0.188 to 0.274 indicating a good homogeneity and mono-modal size distribution. The surface morphology of SLN, NLC, and NE formulations was characterised by TEM. The outer microscopic morphology of all particles was nearly spherical with no effect of the CA content on the particle morphology (Figure 2 ). The particle size correlated well with that measured using PCS.
Drug E.E
The effect of CA loading on the drug E.E of NLC is shown in Figure 3 . Drug E.E of NLC was found to be higher than the SLN with the same total lipid content and increased with the increase of CA content in the matrix. 
Differential scanning calorimetry
CP revealed two peaks at 43.04°C and 52.78°C reflecting two distinct polymorphic forms. According to literature, the peak at 43.04°C is attributed to the polymorphic form whereas the peak at 52.78°C can be attributed either to the most stable polymorphic form (β) (Saupe et al., 2005) . It was observed that the melting point and onset temperature of the nanoparticles were lower than CP and showed a linear relationship with the liquid lipid (CA) content (Figure 4) . The CI or percentage of the lipid matrix that has recrystallised during storage time of SLN and NLC was calculated by comparing the enthalpy of SLN and NLC with the enthalpy of bulk lipid [equation (2)]. Table 2 shows the decrease in degree of crystallinity with the increase of the CA content in NLC. The melting event was absent in nanoemulsions. Figure 5 shows the release of MFA from SLN, NLC formulations with different CA content, and NE as a function of time. SLN and all NLC formulations showed a biphasic drug release with initial burst release followed by sustained release. The results showed that the cumulative amount of drug released from SLN, NLC 10, NLC 15, NLC 25, NLC 35, NLC 40, and NE after 9 hr. was 31.57%, 34.06%, 34.86%, 37.39%, 40.47%, 45.10%, 61.15% respectively. It should be noted that the release rate of MFA increased from NLC with increasing oil content and the initial release of MFA from all NLC and SLN formulation was faster then the one from the nanoemulsion. Concerning the release model, the drug release data was fitted into different models. The % cumulative drug released from SLN and all NLC formulations showed a linear relationship with the square root of time (r 2 = 0.9214, 0.9733, 0.9831, 0.9619, 0.9719, 0.9415 for SLN, NLC 10, NLC 15, NLC 25, NLC35, NLC40, respectively), and therefore, the release profile of MFA from SLN and NLC formulations may be demonstrated by Higuchi model (Higuchi, 1962) . A linear relationship between % cumulative drug release and time (r 2 = 0.975) was found in case of NE showing zero-order kinetics. Figure 6 shows that the occlusion factor was dependent on the CA loading of the formulation. The occlusion factor of SLN, and NLC10 was relatively high and the increase of CA loading in NLC led to the decrease in the occlusion factor.
In vitro release studies
Occlusivity
Storage stability studies
The effect of CA content on the storage stability of NLC at 4 ± 1°C, 25 ± 1°C, and 40 ± 1°C over time (21 days) was studied. At 4 ± 1°C and 25 ± 1°C, NLC and NE showed good stability during the period of storage (21 days) essentially excluding phase separation, changes in physical characteristics, and turbidity; whereas at 40 ± 1°C, NLC showed slight increase in turbidity. The PCS measurements showed that particle sizes of all NLC formulations and NE showed insignificant difference (p > 0.05, ANOVA) when stored at 4 ± 1°C and 25 ± 1°C, while increased significantly (p < 0.05, ANOVA) in NLC formulations at 40 ± 1°C with a PI value ranging between 0.2 and 0.3. In contrast, SLN showed increase in turbidity, and a significant increase (p < 0.05, ANOVA) in particle size at 25 ± 1°C and 40 ± 1°C during the period of storage (21 days) ( Figure 7 ). All NLC formulations exhibited a good ability to reduce the drug expulsion during the period of storage (21 days) at 4 ± 1°C, 25 ± 1°C and 40 ± 1°C, while precipitates of drug were observed by optical microscopy in NE, and SLN resulting into decrease in encapsulation efficiency on storage at all temperatures. ZP of the NLC, and NE did not vary significantly (p > 0.05, ANOVA) during the period of storage (21 days) at 4 ± 1°C, 25 ± 1°C indicating a good physical stability (Figure 8 ). 
Discussion
Selection of lipid matrix
The selection of the proper lipid matrix components by means of solubility screening is a determinant of the drug encapsulation efficiency of NLC. It is expected that high solubility of the drug in the lipid matrix would result in high encapsulation efficiency of the final formulation (Muller et al., 2000) . Figure 1 show that among all liquid lipids selected for solubility screening, MFA has highest solubility in CA. CA is C-8 straight chain fatty acid with MW 144.21 g/mol, boiling point 237°C and melting point 16-17°C, present in butter, palm oil and coconut oil. It was selected as liquid lipid component for NLC formulation. T80 and PG were used as surfactant and co-surfactant, respectively. NLC formulations were prepared using microemulsion template technique. It is novel entropy driven engineering process to engineer stable lipid-based nanoparticles by directly cooling the hot oil-in-water microemulsion template with no dilution of the system. Further, this process avoids the use of expensive and hazardous solvents, mechanical homogenisers and sonicators and can easily be adapted to include different types of drugs Mumper, 2002, 2003; Cui et al., 2003) .
Physicochemical characterisation of SLN, NLC and NE
No aggregated particles and no drug crystals were seen in all formulations on optical microscopy immediately after production. Table 1 shows the effect of CA concentration on size and homogeneity of the nanoparticles as measured by PCS. SLN exhibited larger particle size as well as high PI value, and it was found that the inclusion of CA in the NLC led to a significant reduction in the particle size and PI value (p < 0.05). NE showed the smallest particle size as well as lowest PI value. These findings are in agreement with that reported by Garcia-Fuentes et al. (2005) and Ali et al. (2010) . Our results are in contrast to the work of Lin et al. (2007) who found that particle size of NLC prepared using monocaprate (solid lipid), and medium chain triglyceride (liquid lipid) depended on the content of liquid lipid loading. They observed an increase in the particle size of NLC on increasing the liquid lipid content up to 20 wt% followed by a dramatic decrease in particle size on further increasing the liquid lipid content up to 30 wt%. This change was attributed to the fact that the nanoparticles could encapsulate liquid oil up to 20 wt%, and the sizes of the particles increased due to the swollen core of the particles loaded with liquid lipid. The size of the nanoparticles decreased abruptly when the content of liquid lipid exceeded 20 wt% probably due to the expulsion of the excess of liquid lipid during the lipid crystallisation process. In another report, particle size of NLC containing medium chain triglyceride as liquid lipid and produced by hot high pressure homogenisation did not depend on the content of liquid lipid loading (Teeranachaideekul et al., 2007 (Teeranachaideekul et al., , 2008 . Differences in the results of various studies may be attributed to the difference in the composition of NLC, and the method of production used (Saupe et al., 2006; Lin et al., 2007 ). The relatively large particle size of SLN compared to NLC and NE (Table 1) may be attributed to the relatively high viscosity of the melted lipid phase containing pure CP. Zeta potential measures the surface charge of the nanoparticles and allows the predictions of their storage stability. ZP values of all developed formulations were between −17 and −31 mV (Table 1) indicating a good physical stability. From the literature, particle aggregation is less likely to occur for particles with zeta potential values between -30mV and -60mV due to electric repulsion (Muller et al., 2000) . In addition, the steric hindrance from the non-ionic surfactant(s) (T80) has an additional effect in increasing the particle stability. It gets adsorbed on the nanoparticles surface and thereby increases the steric repulsion between particles (Lim and Kim, 2002) . The effect of the liquid lipid percentage on the nanoparticle morphology was negligible as shown by TEM analysis. The TEM images showed that SLN, NLC, and NE particles were similar in shape, but differed in size (Figure 2 ). With regard to the influence of the amount of lipid on NLC formulation, our study have demonstrate the feasibility of producing NLC up to a lipid concentration of 100mg/ml. Samples having the total amount of lipid phase more than 10% w/v were turbid and did not turn clear even after prolonged stirring at 65°C.
Drug E.E
With increase in the proportion of the CA in NLC, an increase in drug E.E was observed (Figure 3) . It was reported that the prerequisite to obtain high drug loading is the creation of less ordered solid matrix in lipid nanoparticles. For a number of drugs, the solubility in oils is higher than their solubility in solid lipids and the incorporation of liquid lipid to solid lipid can lead to massive crystal order disturbances in the matrix of lipid nanoparticles leading to improved drug encapsulation efficiency and a reduced drug leakage during storage (Muller et al., 2002b; Garcia-Fuentes et al., 2005) . In our study, it was clear that the E.E of NLC were enhanced with increasing the content of CA. The high solubility of MFA in CA could have played the important role to improve the drug incorporation in NLC and NE. Our findings are in agreement with that reported by Dai et al. (2010) . They observed that the E.E of NLC was enhanced with increasing the content of liquid lipid.
Differential scanning calorimetry
The solid state of the nanoparticles must be verified as their potential benefits, e.g., stronger immobilisation of incorporated drugs, or stability against coalescence, mainly rely on their solid state (Bunjes and Koch, 2005) . DSC analysis is mainly used for investigating the solid state of the NLCs. The results of DSC revealed that the thermal behaviour of the CP was dramatically changed on converting it into nanoparticulate form. An onset temperature higher than 40°C was attained in all the formulations, which is the main prerequisite for the preparation of lipid nanoparticles for topical drug delivery (Teeranachaideekul et al., 2007) . The melting point of lipid nanoparticles (SLN and NLC) was lower than the bulk lipid (CP) and the depression became more pronounced with increasing the amount of CA in NLC (Figure 4 ). This is in agreement with the previous research (Doktorovovaa et al., 2010) . According to the Gibbs-Thomson equation (Jackson and McKenna, 1990 ) for a spherical solid particle of diameter x, melting point depression is inversely proportional to the size of the nanoparticle
T mB bulk melting temperature The depression in melting point with increasing content of CA in NLC could be attributed to the decrease in particle size of NLC and can explained by the Gibbs-Thomson equation. As suggested in the literature, the presence of surfactants and the interaction of solid lipid with the liquid lipid could also be responsible for the depression of Bunjes et al. (1996) , Jenning et al. (2000) and Zimmermann et al. (2005) . Table 2 shows that the enthalpy and CI of NLC was lower than that of the SLN and CP and the depression of CI became more pronounced in NLC with higher content of the CA. The perfect crystal structure of CP in SLN needed higher energy to overcome lattice force, the addition of the liquid lipid distorts the crystalline structure of CP, and could be responsible for the depression of CI and enthalpy (Muller et al., 2002a (Muller et al., , 2002b .
In vitro release
The cumulative percentage release of MFA from all the formulations was investigated for a period of 9 hr., where the sink conditions were maintained using 50 mL acetate buffer (pH 6. 0) containing1% w/v CTAB. MFA is a lipophilic molecule. Park and Choi, (2006) reported that the dissolution rate of MFA was substantially enhanced in phosphate buffer medium (pH 6.8) containing CTAB. Figure 5 shows that the drug release rate depends on the concentration of CA in the formulation. It was indicated that the rate of drug release from lipid nanoparticles was enhanced significantly as the amount of CA increased. It was indicated that the rate of drug release from lipid nanoparticles was enhanced significantly as the amount of CA increased. As a result, NLC with 40% CA had high release rate (45.10%), compared to SLN (31.57%) with no CA content probably due to the faster drug diffusion rate via mixed matrix of solid lipid and liquid lipid than that of through solid lipid matrix. The size effect may also partly explain the low release from the larger size SLN. The prerequisite for fast drug release are the small molecular size, large surface area, and a high drug ofile olease prdiffusion coefficient (Zur Muhlen et al., 1998; Zhang et al., 2008) . The reduced drug diffusion mobility in SLN with large particle could explain the decreased drug release rate. For NLCs with various liquid lipid percentages, the higher the liquid lipid loading, smaller will be the particle size, so higher would be the drug release. In addition, the incorporation of liquid lipid into solid lipid matrix causes the decrease in the crystallinity of the system and might allow the loaded drug to release easily. Our results are in contrast to the observations of Wang et al. (2009) who demonstrated the highest release of drug/prodrug tested from SLN, followed by the NLC and lipid emulsion (LE). Regarding the release kinetics of MFA from SLN and NLC, a biphasic pattern with burst drug release at the initial stage and sustained drug release subsequently was found in contrast to the observations of Patlolla et al. (2010) . They observed zero order release pattern for celecoxib (Cxb) from Cxb-NLC. Our finding is in agreement with the results of Zhang et al. (2010) who observed a biphasic release pattern in case of dihydroartemisinin NLC. The observed biphasic release pattern can be explained by the drug enriched shell model proposed for lipid nanoparticles (Han et al. 2008 ) and might be beneficial in transdermal application. The initial burst release can be due to the diffusion of unentrapped drug and might ensure the faster onset of action. The slow and continuous release of drug in the second phase suggests the slow diffusion of the drug dispersed in the solid matrix of lipid nanoparticles and would maintain a certain level of drug in the skin over a prolonged period of time. The observed differences in the release pattern could be related to the effect of lipid matrix composition, the drug load, and the surfactant type and concentration used (Muller et al., 2002a (Muller et al., , 2002b ).
Occlusion test
The occlusion factor (F) is an important issue with respect to the use of lipid nanoparticles as drug carriers for derrmal application. It is well documented in the literature that SLN possess occlusive properties. As shown in Figure 6 the occlusion factor of SLN was highest among all the formulations. Although, the incorporation of CA into the matrix of SLN resulted into the decrease in occlusion factor, yet the NLC formulations with CA content upto 35% showed significant occlusion effect (occlusion factor above 40) after 24 hr. and 48 hr. The occlusion factor depends upon the sample volume, particle size, crystallinity, lipid concentration and type of colloidal systems (Wissing and Muller, 2003; Teeranachaideekul et al., 2008) . As the occlusion factor is directly related to the crystallinity of the lipid matrix, the higher crystallinity of SLN explains its higher occlusivity compared to NLC and NE. The solid state of the lipid matrix in SLN and NLC would facilitate the film formation on the skin that would further enhance drug permeation into and through the skin makes them suitable for dermal application.
Storage stability studies
The MFA-NLC displayed better stability than MFA-SLN, and MFA-NE at 4 ± 1°C and 25 ± 1°C during the period of storage (21 days) characteristics. Increase in particle size observed in all NLC dispersions stored at 40 ± 1°C may be due to the possible aggregation of particles. The increase in the kinetic energy of system at high temperature (40 ± 1°C) could accelerate the collision of particles, and consequently increased the chances of aggregation of particles. No change in drug encapsulation efficiency was observed in NLC with time at 4 ± 1°C and 25 ± 1°C during the period of storage (21 days). This may be attributed to the fact that the enhancement of crystal disturbances within the NLC matrix (lattice effect). The interaction of liquid lipid with the crystalline solid lipid matrix in NLC provide enough space to accommodate drug molecules and decrease the probability of drug expulsion during storage (Teeranachaideekul et al., 2007; Junyaprasert et al., 2009 ).
Conclusions
The NLCs might be considered as an interesting tool as drug carrier and a proper blend of CP and CA may have advantages as a matrix material for the manufacture of the NLCs. The CA behaves as an impurity in the solid lipid matrix and plays an important role in the development of less crystalline system thus enabling high accommodation of drug molecules in NLC. The incorporation of CA in the NLC matrix confers better storage stability and higher suitability for the controlled release. Results are encouraging and confirm the possibility to prepare CA containing NLC. Further studies to elucidate the in vivo use of these nanoparticles for dermal application are in progress.
